UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Sep 08, 2020
- Advocacy organizations in Argentina, Hungary, Russia and the U.S awarded funding -   - Total of 32 projects have been awarded funding since Awards inception in 2015 - SOUTH PLAINFIELD, N.J. , Sept. 8, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the winners of its
Additional Formats
Sep 03, 2020
SOUTH PLAINFIELD, N.J. , Sept. 3, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Cantor Virtual Global Healthcare Conference on Thursday, September 17 th at 9:20 a.m. ET .
Additional Formats
Aug 26, 2020
SOUTH PLAINFIELD, N.J. , Aug. 26, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company achieved a $20 million milestone payment from Roche under its License and Collaboration Agreement. The milestone payment was triggered by the first commercial sale of
Additional Formats
Aug 21, 2020
SOUTH PLAINFIELD, N.J. , Aug. 21, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units ("RSUs"), each representing
Additional Formats
Aug 17, 2020
- Marketing Authorization Application (MAA) based on data from multiple pivotal trials in infants, children and adult patients with SMA -   - Milestone triggers $15M payment from Roche - SOUTH PLAINFIELD, N.J. , Aug. 17, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Aug 07, 2020
- Evrysdi represents the first at home, oral treatment approved for infants, children and adults with all SMA types-   - Marketing Authorization Application submission to European Medicines Agency is imminent -   - Risdiplam is the first approved therapy discovered and developed from PTC
Additional Formats
Aug 06, 2020
- Senior Vice President of Corporate and Patient Relations recognized as one of the 100 most inspiring people in the life-sciences industry - SOUTH PLAINFIELD, N.J. , Aug. 6, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate
Additional Formats
Aug 05, 2020
- Strong Emflaza® 2Q 2020 performance with 30% YoY net product revenue increase -   - Initiated PTC299 trial in COVID-19 in multiple countries -   - Initiated clinical trial with PTC857, identified from Bio-e platform -   - Greater than $1B in cash to accelerate pipeline growth - SOUTH PLAINFIELD,
Additional Formats
Jul 22, 2020
SOUTH PLAINFIELD, N.J. , July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on Wednesday, August 5,
Additional Formats
Jul 21, 2020
SOUTH PLAINFIELD, N.J. , July 21, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET .
Additional Formats